Medical Conditions and Their Commonly Used Drugs

January 2007
Complete Guide to Prescription & Nonprescription Drugs 2012;2007, pxxii
The article presents a list of medical conditions and the commonly used drugs for them, including drugs for acute myocardial infarction, AIDS and HIV infection and Alzheimer's disease.


Related Articles

  • Coreg OK'd for expanded use.  // Drug Topics;4/7/2003, Vol. 147 Issue 7, p7 

    Reports on the U.S. Food and Drug Administration's (FDA) approval of carvedilol for use in patients who have had a myocardial infarction (MI) and who have left ventricular dysfunction. Indication for essential hypertension; Reduction of the risk of mortality.

  • Focus on donepezil. Lipson, Loren G.; Rho, Jay P.; Chow, Moses S.S. // Formulary;Jul97, Vol. 32 Issue 7, p677 

    Provides information on the drug Donepezil HCl approved by the Food and Drug Administration for the treatment of Alzheimer's disease. Chemistry and pharmacology of the drug; Pharmacokinetics; Result of the clinical trials conducted on the drugs; Adverse effects of the drug; Dosing and...

  • Drug watch: Alzheimer's disease.  // Formulary;May99, Vol. 34 Issue 5, p470 

    Lists drugs for Alzheimer's disease with their proposed formulation and status given by the Food and Drug Administration in the United States. Includes galanthamine; Lazabemide; Memantine; SB202026; Propentofylline; Rivastigmine; Olanzapine; Selegiline; Tacrine; AF-102B; Metrifonate;...

  • Efficacy of FPF 1070 (Cerebrolysin) in Patients with Alzheimer's Disease: A Multicentre, Randomised, Double-Blind, Placebo-Controlled Trial. Shifu, X.; Heqin, Y.; Peifen, Y. // Clinical Drug Investigation;2000, Vol. 19 Issue 1, p43 

    Objective: This study evaluated the efficacy and tolerability of FPF 1070 (cerebrolysin) in patients with mild to moderately severe Alzheimer's disease (AD). Methods: The trial was of a multicentre, double-blind, parallel-group design. 157 patients aged 55 to 85 years were randomised to...

  • Tacrine and Alzheimer disease.  // WHO Drug Information;1999, Vol. 13 Issue 1, p7 

    Reports that the Dementia Trialists Collaboration Group has carried out a meta-analysis of tacrine in patients with Alzheimer disease. Determination of the effects of tacrine in symptoms in terms of cognitive performance, clinical global impression of change, behavior and functional autonomy;...

  • Most AD drug treatment complies with guidelines in France.  // PharmacoEconomics & Outcomes News;7/21/2012, Issue 658, p6 

    The article discusses research on the use of anti-Alzheimer's drugs in France, referencing a study by K. Tifratene and colleagues published in the June 20, 2012 issue of "Pharmacoepidemiology."

  • New Drugs for Alzheimer's Disease. Delagarza, Vincent W. // American Family Physician;10/1/1998, Vol. 58 Issue 5, p1175 

    Presents information on Alzheimer's disease, and drugs which are used in the treatment of the disease. Information on the characteristics of Alzheimer's disease; Identification on the drugs used in the treatment of the disease; Examination of the relationship between amyloid plaques,...

  • Alzheimer's Treatments Rush to a Growing Market. Jarvis, Lisa // Chemical Market Reporter;03/19/2001, Vol. 259 Issue 12, p5 

    Discusses the market growth of drugs for Alzheimer's disease (AD) in the United States (U.S.). Value of the AD drug market in 1999; Forecast on the growth rate of AD drugs by 2006; Details on the AD drugs approved in the U.S.

  • Assault on Alzheimer's. Tarlach, Gemma M. // Drug Topics;6/15/98, Vol. 142 Issue 12, p49 

    Reports that a number of pharmaceutical firms are developing drugs to treat Alzheimer's and its symptoms. Information on phase II trials of compound AIT-082 in a number of patients by NeoTherapeutics of Irvine, California; What preclinical studies indicated; Release of guidelines for agitation...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics